Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10484771 | Value in Health | 2015 | 9 Pages |
Abstract
Our analysis suggests that erlotinib is the preferred first-line treatment for advanced epithelial growth factor receptor mutation-positive non-small-cell lung cancer. Further research comparing erlotinib and afatinib is potentially justified, although accurate data are needed on the required cost and sample size of the trial.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jie PhD, MSPH, Tien Ho PharmD, Pin PharmD, Amanda PharmD, Maher PharmD, Leslie PhD,